Updated Jul 16, 2026
Fountain Nathan B has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $14K.
Nathan B. Fountain is listed as a Director of Acumen Pharmaceuticals, Inc. in SEC filings as of 2026-06-05. Beyond this board role, there is no additional publicly available biographical detail provided in the SEC context provided.
| Role | Director |
|---|---|
| Notability | 25/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-10 | ABOS | Acumen Pharmaceuticals, Inc. | S — Open-market sale | 6.4K | $2.23 | $14K |
| 2026-06-05 | ABOS | Acumen Pharmaceuticals, Inc. | A — Grant or award | 35.5K | $0.00 |
Nathan B. Fountain is listed as a Director of Acumen Pharmaceuticals, Inc. in SEC filings as of 2026-06-05. Beyond this board role, there is no additional publicly available biographical detail provided in the SEC context provided.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($14K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Fountain Nathan B profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.